A year ago, HKEX opened the door to pre-revenue biotech companies and new economy companies with non-standard share structures for the first time, ushering in the most significant change to Hong Kong’s listing regime in 25 years.
Already our market has become more vibrant and diverse. So far a total of 40 new economy companies have gone public in Hong Kong, raising HK$150.4 billion – or over half of our total IPO funds raised during the period. On the biotech side in particular, we are starting to see a growing biotech ecosystem with nine biotech companies having listed already and more in the pipeline.
In just a year, the new listing regime has enhanced Hong Kong’s attractiveness as a capital raising hub for a new generation of companies – but more must be done. HKEX will continue to enhance the competitiveness of the Hong Kong financial market and reinforce Hong Kong’s position as a leading global financial centre.